Your session is about to expire
← Back to Search
Talazoparib + Avelumab for Breast Cancer
Study Summary
This trial is testing a new cancer treatment combining two drugs. It will assess how well the treatment works and how safe it is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 1 & 2 trial • 40 Patients • NCT02116777Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant or breastfeeding.I have not had any cancer except for non-melanoma skin cancer in the last 2 years.I have not received a live vaccine in the last 30 days.You are expected to live for at least 3 more months.I haven't taken strong P-gp inhibitors in the last week.I have not had major heart problems or strokes in the last 6 months.My advanced breast cancer cannot be cured with surgery or radiotherapy, but it can be biopsied.I have fully recovered from my recent surgery.I haven't had radiation on more than 20% of my bone marrow.Your heart's electrical activity, as shown in a specific test, meets certain standards.I do not have any serious, uncontrolled health issues or infections.I agree to have multiple biopsies during the study.I have had treatments before, but my last treatment was at least 2 weeks ago.I am not pregnant or have been without a menstrual period for at least 12 months.I, or my legal representative, can understand and follow the study's requirements and have signed the consent form.I have a history of specific lung conditions or signs of lung inflammation on a CT scan.I have a stomach or intestine problem that affects how I absorb medication.I don't have any health issues that would affect the study or stop me from completing it.I have been treated with PARP inhibitors before.My condition worsened within 6 months while on anti-PD-1 or PD-L1 therapy.I have brain metastases that have not been treated.I have not had a severe infection, recent antibiotics, or chronic HIV or hepatitis B.I have had a bone marrow or organ transplant.I do not have any severe illnesses that would make it unsafe for me to join the study.I have had tuberculosis in the past.I am fully active or restricted in physically strenuous activity but can do light work.I have not had signs of infection in the last 2 weeks.I am 18 years old or older.I have an autoimmune disease treated with medication in the last 2 years.I can swallow pills whole.My liver, kidneys, and blood cells are functioning well.Your disease can be seen on a scan using specific guidelines.I have an immune system disorder or am taking medication that weakens my immune system.
- Group 1: Phase I/Phase II
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper limit of people participating in this medical experiment?
"Presently, this clinical trial is not seeking candidates. It was initially posted on April 17th 2019 and last updated October 10th 2022. Those in search of other studies may be interested to know that there are 2596 trials actively recruiting breast cancer patients and 162 trials for Talazoparib currently searching for participants."
Is recruitment for this research still open?
"Currently, no new participants are needed for this particular trial which was first posted in April 2019 and most recently updated on October 10th 2022. If you're looking for other opportunities to participate in clinical trials related to breast cancer, there are 2596 active studies available; those interested in Talazoparib can find 162 separate medical research initiatives enrolling now."
What is the purpose of Talazoparib consumption?
"Talazoparib is often utilized to manage advanced directives, as well as brca1 gene mutations, merkel cell carcinoma and several types of malignant neoplasms."
What other investigations have been conducted on Talazoparib?
"Talazoparib was initially researched at City of Hope in 2010, and since then over 70 clinical trials have been completed. Currently 162 active studies are being conducted with a significant presence in Washington D.C.."
Share this study with friends
Copy Link
Messenger